Regenxbio (RGNX) Fundamental Analysis: Revenue, Earnings & Valuation

6.83 / 10

Outperform

Fundamental rating is Outperform (6.8/10). Strengths include high Profit‑MV, Inventory turnover, Asset‑MV, Revenue‑MV and Cash‑MV scores. Weak points are Income‑tax/Profit ratio, Current assets turnover, low Gross margin and modest Cost‑of‑sales, indicating some efficiency concerns.

Analysis Checks(7/10)

Revenue-MV

Value-1.27

Score3/3

Weight19.83%

1M Return9.51%

Inventory turnover ratio

Value106.57

Score3/3

Weight12.11%

1M Return6.65%

Gross profit margin (%)

Value88.09

Score0/3

Weight-5.81%

1M Return-5.42%

Profit-MV

Value0.68

Score2/3

Weight11.39%

1M Return6.36%

Income tax / Total profit (%)

Value22.35

Score1/3

Weight0.28%

1M Return0.21%

Current assets turnover ratio

Value0.61

Score1/3

Weight-0.25%

1M Return-0.17%

Fixed assets turnover ratio

Value1.05

Score2/3

Weight0.01%

1M Return0.01%

Cost of sales ratio (%)

Value11.91

Score2/3

Weight-4.67%

1M Return-3.62%

Asset-MV

Value-0.55

Score2/3

Weight27.83%

1M Return13.10%

Cash-MV

Value0.03

Score3/3

Weight39.27%

1M Return15.07%

Is RGNX fundamentally strong?

RGNX scores 6.83/10 on fundamentals and holds a Discounted valuation at present. Backed by its -107.00% ROE, -113.75% net margin, -2.25 P/E ratio, 4.25 P/B ratio, and 18.08% earnings growth, these metrics solidify its Outperform investment rating.